RET and medullary thyroid gland carcinoma: The European Medicines Agency (EMA) and the Food and Drug Agency (FDA) have recently approved the RET-selective inhibitor (RETi) selpercatinib in RET fusion-positive advanced NSCLC and PTC and RET-mutant MTC (33, 34).